PNC Financial Services Group
IOVA icon

PNC Financial Services Group’s Iovance Biotherapeutics IOVA Stock Holding History

PNC Financial Services Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216 Sell
52
-25,000
-100% -$95K ﹤0.01% 5094
2026
Q1 		$87.9K Sell
25,052
-25,796
-51% -$82.5K ﹤0.01% 2902
2025
Q4 		$139K Sell
50,848
-208
-0.4% -$481 ﹤0.01% 2569
2025
Q3 		$111K Buy
51,056
+50,834
+22,898% +$120K ﹤0.01% 2742
2025
Q2 		$382 Sell
222
-1,546
-87% -$3.85K ﹤0.01% 4716
2025
Q1 		$5.89K Buy
1,768
+1,159
+190% +$5.98K ﹤0.01% 4002
2024
Q4 		$4.51K Sell
609
-322
-35% -$2.98K ﹤0.01% 4070
2024
Q3 		$8.74K Sell
931
-2,097
-69% -$19.9K ﹤0.01% 3846
2024
Q2 		$24.3K Buy
3,028
+1,684
+125% +$18K ﹤0.01% 3386
2024
Q1 		$19.9K Buy
1,344
+433
+48% +$5.04K ﹤0.01% 3450
2023
Q4 		$7.41K Buy
911
+573
+170% +$3K ﹤0.01% 3836
2023
Q3 		$1.54K Buy
338
+172
+104% +$1.12K ﹤0.01% 4297
2023
Q2 		$1.17K Hold
166
– – ﹤0.01% 4481
2023
Q1 		$1.01K Buy
166
+118
+246% +$814 ﹤0.01% 4437
2022
Q4 		$306 Sell
48
-48
-50% -$375 ﹤0.01% 4592
2022
Q3 		$0 Sell
96
-108
-53% -$1.25K ﹤0.01% 4529
2022
Q2 		$1K Sell
204
-50
-20% -$655 ﹤0.01% 4347
2022
Q1 		$4K Sell
254
-2,003
-89% -$31K ﹤0.01% 4054
2021
Q4 		$42K Sell
2,257
-2,424
-52% -$53.4K ﹤0.01% 3204
2021
Q3 		$116K Buy
4,681
+3,992
+579% +$94.1K ﹤0.01% 2539
2021
Q2 		$18K Buy
689
+307
+80% +$7.98K ﹤0.01% 3517
2021
Q1 		$12K Buy
382
+44
+13% +$1.82K ﹤0.01% 3587
2020
Q4 		$16K Buy
338
+15
+5% +$596 ﹤0.01% 3423
2020
Q3 		$10K Sell
323
-35
-10% -$1.07K ﹤0.01% 3496
2020
Q2 		$9K Buy
358
+246
+220% +$8.09K ﹤0.01% 3494
2020
Q1 		$3K Buy
112
+12
+12% +$318 ﹤0.01% 3677
2019
Q4 		$3K Hold
100
– – ﹤0.01% 3728
2019
Q3 		$2K Hold
100
– – ﹤0.01% 3857
2019
Q2 		$2K Hold
100
– – ﹤0.01% 3866
2019
Q1 		$1K Hold
100
– – ﹤0.01% 3954
2018
Q4 		$1K Sell
100
-1,000
-91% -$9.64K ﹤0.01% 3960
2018
Q3 		$13K Buy
1,100
+100
+10% +$1.42K ﹤0.01% 3578
2018
Q2 		$12K Hold
1,000
– – ﹤0.01% 3625
2018
Q1 		$16K Hold
1,000
– – ﹤0.01% 3530
2017
Q4 		$8K Hold
1,000
– – ﹤0.01% 3751
2017
Q3 		$8K Sell
1,000
-37
-4% -$234 ﹤0.01% 3755
2017
Q2 		$8K Buy
1,037
+37
+4% +$235 ﹤0.01% 3662
2017
Q1 		$8K Hold
1,000
– – ﹤0.01% 3606
2016
Q4 		$6K Hold
1,000
– – ﹤0.01% 3628
2016
Q3 		$8K Hold
1,000
– – ﹤0.01% 3542
2016
Q2 		$8K Hold
1,000
– – ﹤0.01% 3642
2016
Q1 		$6K Hold
1,000
– – ﹤0.01% 3761
2015
Q4 		$8K Buy
+1,000
New +$6.94K ﹤0.01% 3679

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

PNC Financial Services Group's IOVA Position: Q2 2026 in Review

PNC Financial Services Group reduced its Iovance Biotherapeutics (IOVA) stake by 100% in Q2 2026, selling an estimated $95K and leaving 52 shares worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #5094.

PNC Financial Services Group first reported a position in IOVA in Q4 2015 and has held it in 43 quarters since. The position peaked at $139K in Q4 2025. 120 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • PNC Financial Services Group held 52 shares of Iovance Biotherapeutics worth $216 as of Q2 2026.
  • PNC Financial Services Group sold 25,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $95K.
  • Iovance Biotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5094 holding.
  • PNC Financial Services Group first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 43 quarters since.
  • PNC Financial Services Group's Iovance Biotherapeutics position peaked at $139K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.